-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
So far, there is no phase 3 trial showing which drug can improve the survival rate of patients with pleural or peritoneal malignant mesothelioma that has progressed after platinum-based chemotherapy
To evaluate the efficacy and safety of the anti-PD-1 antibody nivolumab in such patients
Recruited 18-year-old patients with pleural or peritoneal mesothelioma who had previously received platinum-based first-line chemotherapy, with imaging evidence suggesting disease progression, ECOG performance status of 0 or 1, and histologically confirmed pleural or peritoneal mesothelioma.
Progression-free survival and overall survival of the two groups
From May 10, 2017 to March 30, 2020, a total of 332 patients were recruited, of which 221 (67%) were randomly assigned to the nivolumab group and 111 (33%) were assigned to the placebo group
The median progression-free survival of nivolumab and placebo groups were 3.
The occurrence of some side effects
The most common treatment-related side effects of grade 3 and above are diarrhea (nivolumab group vs placebo group: 3% vs 2%) and infusion-related reactions (3% vs 0)
In summary, nivolumab represents a potentially beneficial treatment for patients with malignant mesothelioma that has progressed after first-line treatment
Nivolumab represents a potentially beneficial treatment for patients with malignant mesothelioma that has progressed after first-line treatment Nivolumab represents a potentially beneficial treatment for patients with malignant mesothelioma that has progressed after first-line treatment
Original source:
Original source:Dean A Fennell, et al.
Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial.
Leave a message here
